Owkin collaborates with Stanford Medicine on lung cancer and mesothelioma treatment research using AI

Duration:5 mins

Tags: Partnership


Date:November 15th, 2022


Owkin collaborates with Stanford Medicine on lung cancer and mesothelioma treatment research using AI

Owkin, an AI biotech company, is collaborating with Stanford Medicine on research to improve the treatment of lung cancer and mesothelioma.

Using Stanford Medicine’s multimodal patient data, including molecular data, the research aims to discover new biomarkers to improve the development of new treatments. It also aims to further the understanding of treatment-resistance mechanisms and identify potential treatment targets. Owkin, who is sponsoring the research, is contributing its expertise in AI to the study.

The research is led by principal investigator Olivier Gevaert, PhD, Associate Professor of Medicine at the Stanford School of Medicine. 

Dinesh Divakaran, VP of Partnerships, North America at Owkin, said:

The convergence of cutting-edge AI and high-quality patient data is fuelling a revolution in cancer research. We are excited to work with Stanford Medicine to further our mission of using AI to find the right treatment for every patient. 

By combining our expertise in AI with Stanford Medicine’s high-quality multimodal patient data, we hope to better understand the treatment of lung cancer and mesothelioma and make a lasting difference to the lives of patients worldwide.

About Owkin

Owkin is an AI biotechnology company that uses artificial intelligence to find the right treatment for every patient. We bridge shared innovation challenges between biopharma and academic researchers and close the translational gap between complex biology and new drugs. 

We use AI to identify new treatments, de-risk and accelerate clinical trials and build diagnostic tools that improve patient outcomes. Using federated learning, a pioneering collaborative AI framework, Owkin enables medical and biopharma partners to unlock valuable insights from siloed datasets while protecting patient privacy and securing proprietary data. 

Owkin was co-founded by Thomas Clozel MD, a former assistant professor in clinical onco-haematology, and Gilles Wainrib, a pioneer in the field of machine learning in biology, in 2016. Owkin has raised over $300 million and became a unicorn through investments from leading biopharma (Sanofi and BMS) and venture funds (Fidelity, GV and BPI, among others).